Myelodysplastic Syndromes: all 2,165 studies
Page 11 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive, not recruitingNCT05552469Phase 1
- Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan PharmacokineticsCompletedNCT05534620Phase 1
- Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi MielodisplasticheCompletedNCT05520749
- Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With HemoblastosisActive, not recruitingNCT05515029Phase 3
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Active, not recruitingNCT05490446Phase 2
- A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)Active, not recruitingNCT05469737Phase 2/3
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05457556Phase 3
- Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1
- A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSWithdrawnNCT05456269Phase 1
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingNCT05455294Phase 1
- G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCTStatus unknownNCT05453552Phase 2/3
- A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSStatus unknownNCT05448599Phase 1/2
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesActive, not recruitingNCT05428969Phase 1/2
- Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesStatus unknownNCT05426798Phase 1
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
- Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.Status unknownNCT05392647Phase 2
- Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70Status unknownNCT05367583
- A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
- Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesActive, not recruitingNCT05362773Phase 1
- ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)TerminatedNCT05358808Phase 2
- Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell TransplantationCompletedNCT05298930Not applicable
- Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic SyndromeTerminatedNCT05263271Phase 1
- Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid LeukemiaWithdrawnNCT05246384Phase 1/2
- Biologically Focused Therapy of Treatment-Refractory MDS PatientsCompletedNCT05245032
- Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS PatientsTerminatedNCT05237713Phase 2
- Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)TerminatedNCT05223699Phase 1
- A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
- Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic SyndromesCompletedNCT05204953
- A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic MalignanciesWithdrawnNCT05201183Phase 1/2
- Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingNCT05201066Phase 2
- Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.Active, not recruitingNCT05181592Phase 3
- Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948TerminatedNCT05178342Phase 2
- Cryopreserved MMUD BM With PTCy for Hematologic MalignanciesWithdrawnNCT05170828Phase 1
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)SuspendedNCT05168904Phase 1/2
- Muscle Dysfunction in Patients With Haematological DiseasesActive, not recruitingNCT05150561
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05139004Phase 1
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
- Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCTStatus unknownNCT05066958Phase 1/2
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status unknownNCT05061147Phase 1/2
- Pharmacokinetics, Tolerability and Safety of NEX-18aCompletedNCT05048498Phase 1
- Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
- Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT04994808Phase 2
- A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesWithdrawnNCT04985656Phase 2
- Inqovi Maintenance Therapy in Myeloid NeoplasmsActive, not recruitingNCT04980404Phase 1
- Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)CompletedNCT04973280
- Physical Activity in Transfusion Dependent Patients With Myelodysplastic SyndromeWithdrawnNCT04969367
- Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)WithdrawnNCT04953312Not applicable
- Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic SyndromesTerminatedNCT04951778Phase 1
- Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid MalignanciesCompletedNCT04943757Phase 2
- Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)CompletedNCT04942730Phase 2
- A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological MalignanciesTerminatedNCT04937166Phase 1
- Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT04926194Phase 2
- Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeTerminatedNCT04912063Phase 1
- Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 MutationsStatus unknownNCT04906031Phase 2
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsCompletedNCT04902833
- A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic SyndromeActive, not recruitingNCT04900350Phase 1/2
- Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDSWithdrawnNCT04893915Phase 2
- FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesActive, not recruitingNCT04891757Phase 1
- GENOMED4ALL: Improving MDS Classification and Prognosis by AIStatus unknownNCT04889729
- A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
- Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.TerminatedNCT04866056Phase 1/2
- Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic SyndromesActive, not recruitingNCT04861207Phase 2
- Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?CompletedNCT04859218Not applicable
- Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSTerminatedNCT04849910Phase 1/2
- BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDSCompletedNCT04827719Phase 2
- Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSTerminatedNCT04810611Phase 1
- Interplay Between Immune and Metabolic Programs in Myelodysplastic SyndromesCompletedNCT04803721
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingNCT04798339Phase 1/2
- Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceActive, not recruitingNCT04797000Phase 2
- Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood DisordersActive, not recruitingNCT04761770Phase 2
- A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
- Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04734990Phase 1/2
- A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruitingNCT04730258Phase 1/2
- A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic SyndromeCompletedNCT04718844Phase 1
- G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCTStatus unknownNCT04713956Phase 2/3
- Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatCompletedNCT04712942Phase 2
- Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic SyndromesStatus unknownNCT04701229
- A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)TerminatedNCT04691141Phase 1/2
- Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated PatientsCompletedNCT04676945
- CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDSActive, not recruitingNCT04668885Phase 2
- SARS-CoV-2 Donor-Recipient Immunity TransferCompletedNCT04666025
- Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04655755Phase 1/2
- Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme TestCompletedNCT04635384
- Thrombosomes® in Bleeding Thrombocytopenic Patients StudyTerminatedNCT04631211Phase 2
- Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTCompletedNCT04629430Not applicable
- IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT04628338Early Phase 1
- NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSActive, not recruitingNCT04623944Phase 1
- A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04609826Phase 1
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruitingNCT04603001Phase 1
- Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)Status unknownNCT04602273
- Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaTerminatedNCT04550442Phase 1/2
- A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic MalignanciesCompletedNCT04543305Phase 1
- Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS PatientsSuspendedNCT04539236Phase 1/2
- Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
- IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCTCompletedNCT04522895Phase 2
- Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic SyndromeCompletedNCT04515914
- Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2